Compass Therapeutics (CMPX) Assets Average (2018 - 2026)
Compass Therapeutics (CMPX) posted Assets Average of $212.4 million for Q1 2026, down 5.79% sequentially from $225.4 million in Q4 2025, and up 56.24% YoY from $135.9 million in Q1 2025.
Compass Therapeutics (CMPX) Assets Average (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported Assets Average for 9 years, with the latest figure at $212.4 million in Q1 2026.
- Quarterly Assets Average rose 56.24% year-over-year to $212.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $212.4 million (up 56.24% YoY) and the FY2025 annual result came in at $180.0 million, up 21.1% from the prior year.
- Assets Average fell to $212.4 million in Q1 2026 per CMPX's latest filing, from $225.4 million in the prior quarter.
- Over five years, Assets Average peaked at $225.4 million in Q4 2025 and troughed at $124.1 million in Q2 2025.
- A 5-year average of $164.3 million and a median of $159.0 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average soared 199.99% in 2022, then fell 21.66% in 2025.
- Over 5 years, Assets Average stood at $163.7 million in 2022, then declined by 0.17% to $163.5 million in 2023, then dropped by 11.43% to $144.8 million in 2024, then soared by 55.7% to $225.4 million in 2025, then dropped by 5.79% to $212.4 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $212.4 million, $225.4 million, and $174.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | 197.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 197.67 Mn |
| Mar 31, 2026 | 212.38 Mn |
| Dec 31, 2025 | 225.42 Mn |
| Sep 30, 2025 | 173.98 Mn |
| Jun 30, 2025 | 124.07 Mn |
| Mar 31, 2025 | 135.93 Mn |
| Dec 31, 2024 | 144.78 Mn |
| Sep 30, 2024 | 152.38 Mn |
| Jun 30, 2024 | 158.38 Mn |
| Mar 31, 2024 | 159.01 Mn |
| Dec 31, 2023 | 163.46 Mn |
| Sep 30, 2023 | 174.61 Mn |
| Jun 30, 2023 | 183.58 Mn |
| Mar 31, 2023 | 193.81 Mn |
| Dec 31, 2022 | 163.74 Mn |
| Sep 30, 2022 | 134.05 Mn |
| Jun 30, 2022 | 143.41 Mn |
| Mar 31, 2022 | 150.16 Mn |
| Dec 31, 2021 | 94.33 Mn |
| Mar 31, 2021 | 50.05 Mn |